Reports Q1 revenue $93.9M, consensus $86.45M. “We are thrilled to have achieved strong revenue performance in Q1, marked by year-over-year growth of 33%. This reflects our unwavering dedication to making KIMMTRAK accessible to patients who need it,” said Bahija Jallal, Chief Executive Officer of Immunocore (IMCR). “In R&D, we continue to be laser-focused on execution in our oncology franchise with three ongoing Phase 3 trials and a promising early pipeline. We are also excited to have presented the initial MAD data at CROI from our ongoing HIV trial, which, together with our progress in autoimmune, underscores the breadth of our platform.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore price target lowered to $33 from $38 at Mizuho
- Immunocore Holdings: Buy Rating Backed by Promising Strategy and Strong Financials Despite Mixed Study Data
- Immunocore Holdings’ Promising HIV Immunotherapy Advances Justify Buy Rating
- Positive Outlook on Immunocore Holdings’ Innovative HIV Program Justifies Buy Rating
- Immunocore Holdings Reveals Promising HIV Trial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue